Pre-LaunchCleverpetz is currently in pre-launch โ€” join the waitlist to be first when we go live. Join the waitlist โ†’
๐ŸชWe use cookies & process DNA dataGDPR

We use cookies to improve your experience and analyse site traffic. If you order a DNA kit, your pet's genetic data will be processed by our certified lab partner. Privacy Policy ยท Terms of Use

๐Ÿ”’ Strictly Necessary (Required)๐Ÿ“Š Analytics & Performance๐Ÿ“ฃ Marketing & Advertising๐Ÿงฌ DNA Data Processing
๐Ÿ‘ DEMO MODE โ€” Viewing 4 real-world style protocols for Rose, Wes, Bella & Max. Try approving, flagging, or requesting a revision โ€” actions are simulated. ๐Ÿš€ All Portalsโ† Back to Home
๐Ÿฉบ
CLEVERPETZ VET PORTAL
Protocol Review & Approval System
Demo Viewer โ€” Dr. Sarah Chen, DVMโ† Exit Portal
1
Pending Review
2
Approved
0
Flagged
1
Revision Req.
โš ๏ธ
Veterinary Review Responsibility: By approving a protocol, you confirm that the AI-generated supplement recommendations are consistent with evidence-based veterinary nutrition guidelines and do not contraindicate any known conditions for the pet's breed, age, or species. All approved protocols will display your name and credentials to the pet owner. These statements have not been evaluated by the FDA and are not intended to diagnose, treat, cure, or prevent any disease.
๐Ÿพ Roseโ€” Blue Merle Australian Shepherd
3 years ยท Female ยท Owner: Isabelle & Cedric ยท DNA Kit: CP-DNA-2025-0041 ยท Submitted: 2/20/2026
โณ Pending Review
Genetic Marker Risk Scores
Joint Health Risk
72
Immune Function
45
Digestive Sensitivity
38
Skin & Coat Health
61
Cognitive Function
29
Cardiac Risk
18
AI-Generated Protocol (4 recommendations)
#1
Joint Support Liquid Formula
JOINT & MOBILITY ยท 94% DNA match
Rose carries two copies of the COL5A2 variant associated with connective tissue laxity in Australian Shepherds. Her joint health risk score of 72/100 places her in the high-risk tier. Glucosamine HCl (500 mg/serving), MSM (200 mg), and Boswellia extract in this formula directly support synovial fluid production and reduce inflammatory cytokines at the joint level. Early intervention at age 3 is clinically optimal โ€” before degenerative changes become symptomatic.
#2
Immune Boost Liquid Drops
IMMUNE SUPPORT ยท 81% DNA match
The IGHM locus variant detected in Rose's panel is linked to reduced baseline IgA secretion in the gut-associated lymphoid tissue (GALT). Her immune function score of 45 indicates moderate risk. Beta-glucan (150 mg), Astragalus root, and Elderberry extract in this formula have demonstrated efficacy in upregulating mucosal immunity in canine studies. Recommended as a daily maintenance supplement.
#3
Skin & Coat Omega Liquid Supplement
SKIN & COAT ยท 76% DNA match
Rose's PTPN22 variant is associated with elevated Th2 immune skewing, predisposing her to atopic dermatitis and seasonal skin flares common in Merle-patterned Aussies. Omega-3 EPA/DHA (1,200 mg combined) in this formula modulates the arachidonic acid pathway, reducing prostaglandin E2 production. Her skin score of 61 warrants proactive supplementation before allergy season.
#4
Probiotic & Digestive Enzyme Blend
DIGESTIVE HEALTH ยท 68% DNA match
The FUT2 non-secretor variant detected in Rose's panel is associated with reduced Bifidobacterium colonisation and increased intestinal permeability. While her digestive sensitivity score (38) is in the moderate range, the FUT2 variant makes her susceptible to dysbiosis under stress. 10 billion CFU multi-strain probiotic with digestive enzymes (protease, lipase, amylase) will support microbiome resilience.
โš ๏ธ MDR1/ABCB1 GENE ALERT โ€” HIGH-RISK BREED
Blue Merle Australian Shepherd is a herding breed with elevated prevalence of the MDR1 (ABCB1-1ฮ”) mutation, which causes abnormal P-glycoprotein function and increased drug/supplement sensitivity. Key clinical implications: (1) Avoid ivermectin, loperamide, and certain chemotherapy agents. (2) Some herbal compounds (e.g., St. John's Wort) are P-gp inhibitors โ€” none present in this protocol. (3) All supplements in this protocol have been screened and are safe for MDR1-affected dogs. Recommend genetic MDR1 testing if not already performed.
๐Ÿ”ฌ Drug Interaction Screening
LOWJoint Support Liquid Formula+ NSAIDs (Carprofen, Meloxicam)
Glucosamine may have additive anti-inflammatory effects. Monitor for GI upset if used concurrently. Generally safe.
MODERATEJoint Support Liquid Formula+ Anticoagulants (Warfarin)
High-dose glucosamine may theoretically potentiate anticoagulant effects. Monitor INR if pet is on anticoagulant therapy.
HIGHImmune Boost Liquid Drops+ Immunosuppressants (Cyclosporine, Prednisone)
Beta-glucan and Astragalus are immune stimulants. Contraindicated in pets on immunosuppressive therapy โ€” may counteract treatment.
HIGHImmune Boost Liquid Drops+ Chemotherapy agents
Elderberry and immune-stimulating herbs may interfere with chemotherapy protocols. Consult oncologist before use.
MODERATESkin & Coat Omega Liquid Supplement+ Anticoagulants (Warfarin, Aspirin)
Omega-3 EPA/DHA at doses >3g/day can inhibit platelet aggregation. At label dose (1,200 mg), risk is low but monitor in pets on anticoagulants.
LOWSkin & Coat Omega Liquid Supplement+ NSAIDs
Omega-3 and NSAIDs have complementary anti-inflammatory mechanisms. Generally safe and potentially synergistic.
MODERATEProbiotic & Digestive Enzyme Blend+ Antibiotics
Antibiotics may reduce probiotic efficacy. Administer probiotics 2+ hours apart from antibiotics. Continue supplementation for 2 weeks post-antibiotic course.
LOWProbiotic & Digestive Enzyme Blend+ Antifungals (Fluconazole)
Antifungals target pathogenic fungi and do not significantly affect probiotic bacteria strains. Generally safe.
๐Ÿ“ WSAVA/AAFCO Dosage Verification
IngredientProtocol DoseEvidence BasisAAFCO Safe Upper LimitStatus
Glucosamine HCl22 mg/kg/dayWSAVA Nutrition Guidelines 2021No established UL; doses up to 500 mg/kg/day in rodents show no toxicityโœ“ WITHIN LIMITS
MSM (Methylsulfonylmethane)50 mg/kg/dayAragon et al. (2007) โ€” canine OA RCTNOAEL: 1,000 mg/kg/day (rat studies)โœ“ WITHIN LIMITS
Boswellia serrata extract10 mg/kg/dayReichling et al. (2004)No established UL; traditional use at 300 mg/day for 70 kg humanโœ“ WITHIN LIMITS